“On for 8 weeks, off for 4” — that pattern shows up on almost every research protocol. Here’s why cycling matters, what’s actually happening biologically during the off-period, and how to choose cycle lengths that match the compound you’re working with.
Why cycle at all
If a compound is working, why stop? Three reasons, in increasing order of importance:
- Tolerance. Most receptor systems downregulate when chronically stimulated. The same dose produces less effect over time.
- Feedback loops. Compounds that act on the endocrine system (GH axis, GLP-1 axis, etc.) suppress the body’s own production of related hormones. Cycling allows endogenous production to recover.
- Receptor desensitisation. Continuous high-occupancy receptor binding triggers internalisation and slower re-expression. The receptors literally disappear from the cell surface for a while.
None of this means the compound is “burning out” — it’s just biology adapting to the constant signal. Cycling preserves the responsiveness that makes the compound work in the first place.
Three things an off-period does
1. Receptor recovery
Receptor expression on cell surfaces is dynamic. Chronic agonism causes the cell to internalise receptors via endocytosis. New receptor synthesis takes days to weeks depending on the receptor type. An off-period restores full surface receptor density before the next cycle.
2. Endogenous axis recovery
For HPA, HPG, and somatotropic axes, exogenous compounds suppress endogenous production via negative feedback. The hypothalamus stops sending the upstream signal because circulating levels appear adequate. Off-periods let the natural axis re-engage.
3. Tissue-level adaptation reset
Some effects are mediated not by direct receptor activity but by downstream tissue changes (fibroblast activation, collagen synthesis, vascularisation). These adaptations themselves can plateau under continuous stimulus. Time off lets the tissue “rest” at the new baseline.
Cycle lengths by compound class
| Compound class | Standard cycle | Off-period | Why |
|---|---|---|---|
| Short-acting peptides (BPC-157, TB-500, KPV) | 4–8 weeks | 2–4 weeks | Localised effects; tolerance less of a concern but receptor reset still useful |
| GHRH peptides (Tesamorelin, CJC-1295) | 8–16 weeks | 4–8 weeks | GH axis feedback needs full restoration time |
| GHRPs (Ipamorelin, GHRP-2) | 8–12 weeks | 4–6 weeks | Ghrelin receptor desensitisation reverses on multi-week timeline |
| HGH | 3–6 months (minimum) | 8–12 weeks | Downstream effects need months to register; off-period restores natural GH axis |
| IGF-1 LR3 | 4 weeks | 4 weeks | Strong receptor signalling — short on/off prevents downregulation |
| GLP-1 agonists (Semaglutide, Tirzepatide, Retatrutide) | Long-term (months) | Tapered withdrawal | Sudden discontinuation causes rebound; taper rather than cold-stop |
| Intranasal cognitive (Selank, Semax) | 10–14 day pulses | 2–4 weeks | Short pulses prevent tolerance to anxiolytic/nootropic peptide effects |
| Oral nootropics (Adrafinil) | 5 days on, 2 off (weekly), OR 3 weeks on, 1 off | Built into the cycle | Liver enzyme load + dopamine receptor sensitivity |
Designing the off-period
Three rules for setting the off-period:
- It needs to outlast the compound’s plasma half-life by at least 5×. Otherwise the “off-period” still has clinically relevant compound circulating. For most peptides that’s ≥1 week; for GLP-1 agonists that’s ≥4 weeks.
- It needs to match the receptor recovery timeline, not the plasma clearance timeline. Receptor re-expression is usually slower than drug elimination.
- It needs to be long enough to feel the contrast. Part of the value of cycling is being able to compare “on” effects to “off” baseline. A 3-day off-period is too short to register subjective change.
Cycle bridging — what to do during off-weeks
Off-weeks don’t have to be empty. Two common approaches:
- Pure washout. Nothing. Let the body reset fully. Useful when you want a clean baseline before changing protocols.
- Switch class. Move to a compound that works a different system. Example: 8 weeks of Tesamorelin (GH axis), then 4 weeks of BPC-157 (tissue repair) as a bridge while the GH axis recovers. The body is “on” something, just not the same thing.
Per-compound cycle recommendations live on each individual compound page in the peptide library.